Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 8

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 8
---
 selectively target the sodium ion-channel known as “NaV1.7”, which has been genetically validated as a pain receptor in human physiology. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”). Channel’s goal is to develop a novel and proprietary class of NaV blockers that target the body’s peripheral nervous system. Channel’s stock is traded on The NYSE American under the ticker symbol “CHRO”.

On April 16, 2025, Channel, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand, entered into the Merger Agreement, pursuant to which, among other things, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into LNHC, with LNHC continuing as our wholly owned subsidiary and the surviving corporation of the Merger. If the Merger is completed, the business of LNHC will continue as the business of the combined company, which will focus on developing LNHC’s product candidates, and it is anticipated that the combined company will not continue to develop any of Channel’s legacy product candidates.

#### LNHC, Inc.

#### 4020 Stirrup Creek Drive, Suite 110

#### Durham, NC 27703

#### Telephone: (919) 908-2400
LNHC is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3% (“ZELSUVMI”), for the treatment of Molluscum contagiosum (molluscum), was approved by the U.S. Food and Drug Administration (“FDA”) in 2024. LNHC is a subsidiary of Ligand and will remain so until the completion of the Transactions.

#### CHRO Merger Sub Inc.

#### c/o Channel Therapeutics Corporation

#### 4400 Route 9 South, Suite 1000

#### Freehold, NJ 07728
(877) 265-8266

Merger Sub is a wholly-owned subsidiary of Channel and was formed solely for the purpose of carrying out the Merger.

#### The Merger
If the Merger is completed, Merger Sub will merge with and into LNHC, with LNHC surviving the Mer